BR112018071586A2 - uso de beta-agonistas da tireoide - Google Patents

uso de beta-agonistas da tireoide

Info

Publication number
BR112018071586A2
BR112018071586A2 BR112018071586-7A BR112018071586A BR112018071586A2 BR 112018071586 A2 BR112018071586 A2 BR 112018071586A2 BR 112018071586 A BR112018071586 A BR 112018071586A BR 112018071586 A2 BR112018071586 A2 BR 112018071586A2
Authority
BR
Brazil
Prior art keywords
agonists
thyroid beta
thyroid
beta
adrenoleukodystrophy
Prior art date
Application number
BR112018071586-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Jiang Hongjian
Lian Brian
Hanley Rochelle
Dinerman Misha
Erion Mark
Boyer Serge
Original Assignee
Viking Therapeutics, Inc.
Metabasis Therapeutics, Inc.
Jiang Hongjian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viking Therapeutics, Inc., Metabasis Therapeutics, Inc., Jiang Hongjian filed Critical Viking Therapeutics, Inc.
Publication of BR112018071586A2 publication Critical patent/BR112018071586A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112018071586-7A 2016-04-22 2017-04-24 uso de beta-agonistas da tireoide BR112018071586A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326436P 2016-04-22 2016-04-22
US62/326,436 2016-04-22
PCT/US2017/029120 WO2017185087A1 (en) 2016-04-22 2017-04-24 Use of thyroid beta-agonists

Publications (1)

Publication Number Publication Date
BR112018071586A2 true BR112018071586A2 (pt) 2019-02-12

Family

ID=60116400

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071586-7A BR112018071586A2 (pt) 2016-04-22 2017-04-24 uso de beta-agonistas da tireoide

Country Status (10)

Country Link
US (3) US11351183B2 (enExample)
EP (1) EP3445373B1 (enExample)
JP (1) JP6931042B2 (enExample)
KR (1) KR102407059B1 (enExample)
AU (1) AU2017252126B2 (enExample)
BR (1) BR112018071586A2 (enExample)
CA (1) CA3021681C (enExample)
ES (1) ES2992773T3 (enExample)
MX (1) MX385085B (enExample)
WO (1) WO2017185087A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992773T3 (en) 2016-04-22 2024-12-18 Viking Therapeutics Inc Use of thyroid beta-agonists
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
CA2543132A1 (en) 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
SG144145A1 (en) 2004-12-08 2008-07-29 Sirion Therapeutics Inc Methods, assays and compositions for treating retinol-related diseases
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
US20090042857A1 (en) 2006-02-20 2009-02-12 Masuo Yamaoka Novel Pharmaceutical
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
MX344807B (es) 2011-06-21 2017-01-09 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3).
JP2016517883A (ja) 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
JP2018510849A (ja) 2015-02-20 2018-04-19 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ ソベチロムの誘導体
JP6862459B2 (ja) 2016-02-29 2021-04-21 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ヒンジリッド容器およびブランク
KR102407053B1 (ko) 2016-04-22 2022-06-10 바이킹 테라퓨틱스 인코포레이티드 갑상선 베타-작용제의 사용
ES2992773T3 (en) 2016-04-22 2024-12-18 Viking Therapeutics Inc Use of thyroid beta-agonists
KR102331596B1 (ko) 2016-05-18 2021-11-25 오레곤 헬스 앤드 사이언스 유니버시티 소베티롬의 유도체

Also Published As

Publication number Publication date
CA3021681A1 (en) 2017-10-26
EP3445373A4 (en) 2019-12-18
JP2019515033A (ja) 2019-06-06
US12440502B2 (en) 2025-10-14
CA3021681C (en) 2024-09-24
KR102407059B1 (ko) 2022-06-10
EP3445373A1 (en) 2019-02-27
WO2017185087A1 (en) 2017-10-26
MX385085B (es) 2025-03-14
ES2992773T3 (en) 2024-12-18
US20220257618A1 (en) 2022-08-18
US11951114B2 (en) 2024-04-09
AU2017252126A1 (en) 2018-11-08
JP6931042B2 (ja) 2021-09-01
MX2018012900A (es) 2019-07-01
US20250000880A1 (en) 2025-01-02
AU2017252126B2 (en) 2023-02-09
US20190321379A1 (en) 2019-10-24
US11351183B2 (en) 2022-06-07
KR20190039027A (ko) 2019-04-10
EP3445373B1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
ZA202107931B (en) Anti-tau antibodies and methods of use
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
CL2019001381A1 (es) Método para el tratamiento de glomeruloesclerosis segmentaria focal.
BR112017027721A2 (pt) formulação de alta concentração
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
BR112018071586A2 (pt) uso de beta-agonistas da tireoide
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112018071559A2 (pt) uso de beta-agonistas da tireoide
CR20180110A (es) Libobactina para uso en el tratamiento de la mastitis bovina
EA201792492A1 (ru) Aml-антигены и их применение
CL2018003283S1 (es) Automóvil (divisional solicitud 201800156).
UA114708U (uk) Тяговий привід електробуса
EA201890727A1 (ru) Модуляторы взаимодействия сестрина-gator2 и их применение
UA101750U (ru) Применение омега как органопротектора при токсическом гепатите
UA101964U (uk) Застосування декаметоксину як протимікробного засобу проти бактерій виду pseudomonas aeruginosa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]